Cargando…

Rational Design of CXCR4 Specific Antibodies with Elongated CDRs

[Image: see text] The bovine antibody (BLV1H12) which has an ultralong heavy chain complementarity determining region 3 (CDRH3) provides a novel scaffold for antibody engineering. By substituting the extended CDRH3 of BLV1H12 with modified CXCR4 binding peptides that adopt a β-hairpin conformation,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Tao, Liu, Yan, Wang, Ying, Hull, Mitchell, Schultz, Peter G., Wang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120998/ https://www.ncbi.nlm.nih.gov/pubmed/25041362 http://dx.doi.org/10.1021/ja5042447

Ejemplares similares

Antibody Complementarity-Determining Regions (CDRs): A Bridge between Adaptive and Innate Immunity
por: Gabrielli, Elena, et al.
Publicado: (2009)

International Advisory Committee Final Statement on the FCC CDRs
por: Dissertori, Guenther
Publicado: (2019)

Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities
por: Polonelli, Luciano, et al.
Publicado: (2008)

Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes
por: Haberger, Markus, et al.
Publicado: (2014)

CdrS Is a Global Transcriptional Regulator Influencing Cell Division in Haloferax volcanii
por: Liao, Yan, et al.
Publicado: (2021)

Striking Similarities between CDRs in Some mAbs That Neutralize COVID-19
por: Mi, Tianxiong, et al.
Publicado: (2020)

Hyperexpression of CDRs and HWP1 genes negatively impacts on Candida albicans virulence
por: Maras, Bruno, et al.
Publicado: (2021)

Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs
por: Teixeira, Andre A. R., et al.
Publicado: (2022)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

A New in Silico Antibody Similarity Measure Both Identifies Large Sets of Epitope Binders with Distinct CDRs and Accurately Predicts Off-Target Reactivity
por: Musnier, Astrid, et al.
Publicado: (2022)

Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
por: Sokkar, Pandian, et al.
Publicado: (2021)

The Ribbon-Helix-Helix Domain Protein CdrS Regulates the Tubulin Homolog ftsZ2 To Control Cell Division in Archaea
por: Darnell, Cynthia L., et al.
Publicado: (2020)

Rational design of a conformation-specific antibody for the quantification of Aβ oligomers
por: Aprile, Francesco A., et al.
Publicado: (2020)

Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer
por: Litman-Zawadzka, Ala, et al.
Publicado: (2020)

Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates
por: Costa, Maria José, et al.
Publicado: (2019)

Crystal structure of ultra-humanized anti-pTau Fab reveals how germline substitutions humanize CDRs without loss of binding’
por: Brinth, Alette R., et al.
Publicado: (2022)

Mechanistic insights into the rational design of masked antibodies
por: Orozco, Carolina T., et al.
Publicado: (2022)

Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies
por: Zhu, Cheng, et al.
Publicado: (2019)

Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
por: Fernández-Quintero, Monica L., et al.
Publicado: (2022)

Rational Design of Chemically Controlled Antibodies and Protein Therapeutics
por: Marchand, Anthony, et al.
Publicado: (2023)

Rationally Designed Oral DOX Gels for Colon-Specific Administration
por: Li, Jie, et al.
Publicado: (2022)

CXCR4 Expression in Prostate Cancer Progenitor Cells
por: Dubrovska, Anna, et al.
Publicado: (2012)

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications
por: Yang, Yaru, et al.
Publicado: (2023)

Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity
por: Liang, Guang-Quan, et al.
Publicado: (2020)

Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
por: Kontos, Christos, et al.
Publicado: (2020)

Corrigendum: Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
por: Fernández-Quintero, Monica L., et al.
Publicado: (2022)

Rational design of Striga hermonthica-specific seed germination inhibitors
por: Zarban, Randa A, et al.
Publicado: (2021)

CXCL12/CXCR4/CXCR7 axis in placenta tissues of patients with placenta previa
por: Wu, Xia, et al.
Publicado: (2023)

Molecular basis for the antagonistic activity of an anti-CXCR4 antibody
por: Peng, Li, et al.
Publicado: (2015)

A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
por: Sun, Rui, et al.
Publicado: (2021)

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity
por: Li, Zhihai, et al.
Publicado: (2018)

CXCR4 and CXCR3 are two distinct prognostic biomarkers in breast cancer: Database mining for CXCR family members
por: Guo, Kaibo, et al.
Publicado: (2019)

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
por: Peng, Sheng-Bin, et al.
Publicado: (2016)

Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation
por: Onuoha, Shimobi C., et al.
Publicado: (2015)

CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338
por: Pollino, Serena, et al.
Publicado: (2019)

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
por: Kashyap, Manoj K., et al.
Publicado: (2017)

Rational design and validation of an anti-protein kinase C active-state specific antibody based on conformational changes
por: Pena, Darlene Aparecida, et al.
Publicado: (2016)

Computational and Rational Design of Single-Chain Antibody against Tick-Borne Encephalitis Virus for Modifying Its Specificity
por: Baykov, Ivan K., et al.
Publicado: (2021)

Rational Design of Monodisperse Mesoporous Silica Nanoparticles for Phytase Immobilization
por: Xin, Chunling, et al.
Publicado: (2020)

Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength
por: Samuels, Eric R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n20airtr731hug7s8v2kp3q1m1